Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 29;12(17):5635.
doi: 10.3390/jcm12175635.

All-Cause Mortality and Its Predictors in Haemato-Oncology Patients with Febrile Neutropenia

Haim Shmuely  1   2 , Lea Monely  1   2 , Lev Shvidel  2   3
Affiliations

All-Cause Mortality and Its Predictors in Haemato-Oncology Patients with Febrile Neutropenia

Haim Shmuely et al. J Clin Med. .

Abstract

Febrile neutropenia (FN) is one of the most important life-threatening complications in haemato-oncology. Our objective was to report all-cause mortality rates in patients ill with a hematological malignancy (HM) hospitalized with a first FN episode and to identify predictors for mortality. We conducted a historical retrospective cohort study of consecutive patients with an HM, >18 years of age, admitted between January 2012 and August 2018 for a first episode of FN. Data on all-cause mortality 12 months after admission for FN were obtained. The Kaplan-Meier curve was used to describe mortality during the follow-up period. Univariate and multivariable analyses identified predictors for 1,3 and 12-month mortality. One hundred and fifty-eight patients (mean age 69.5, 49.4% males) were included. Overall, 54 patients died (15.8%, 25.9%, and 34.1% died after 1, 3, and 12 months, respectively). Lower serum albumin, higher serum gamma-glutamyl transferase (GGT), lower estimated glomerular filtration rate (eGFR), older age, higher temperature, and lower absolute lymphocyte count at admission were independent predictors of all-cause mortality after 12 months. Further studies are needed to confirm our results and identify therapeutic strategies to improve survival.

Keywords: all-cause mortality; febrile neutropenia; haemato-oncological patients; predictors of mortality.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curve demonstrating the all-cause mortality rate during the 12-month post-admission period. The colored shadow areas indicate a 95% confidence interval.
See this image and copyright information in PMC

References

    1. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–2266. doi: 10.1002/cncr.21847. - DOI - PubMed
    1. Keng M.K., Sekeres M.A. Febrile neutropenia in hematologic malignancies. Curr. Hematol. Malig. Rep. 2013;8:370–383. doi: 10.1007/s11899-013-0171-4. - DOI - PubMed
    1. Al-Tawfiq J.A., Hinedi K., Khairallah H., Saadeh B., Abbasi S., Noureen M., Raza S., Alkhatti A. Epidemiology and source of infection in patients with febrile neutropenia: A ten-year longitudinal study. J. Infect. Public Health. 2019;12:364–366. doi: 10.1016/j.jiph.2018.12.006. - DOI - PubMed
    1. Parodi R.L., Lagrutta M., Tortolo M., Navall E., Rodriguez M.S., Sasia G.F., De Candia L.F., Gruvman M.A., Bottasso O., Greca A.A. A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period. PLoS ONE. 2019;14:e0224299. doi: 10.1371/journal.pone.0224299. - DOI - PMC - PubMed
    1. Weerasubpong B., Makruasi N., Linasmita P., Rattanamongkolgul S. Factors associated with survival outcomes of febrile neutropenia in hematologic malignancy patients. J. Med. Assoc. Thai. 2016;99:S53–S62. - PubMed